NAD+ Metabolism in Aging and Cancer

IF 4.7 2区 医学 Q1 ONCOLOGY Annual Review of Cancer Biology-Series Pub Date : 2019-03-04 DOI:10.1146/ANNUREV-CANCERBIO-030518-055905
T. Demarest, M. Babbar, M. Okur, Xiuli Dan, D. Croteau, Nima B Fakouri, M. Mattson, V. Bohr
{"title":"NAD+ Metabolism in Aging and Cancer","authors":"T. Demarest, M. Babbar, M. Okur, Xiuli Dan, D. Croteau, Nima B Fakouri, M. Mattson, V. Bohr","doi":"10.1146/ANNUREV-CANCERBIO-030518-055905","DOIUrl":null,"url":null,"abstract":"Aging is a major risk factor for many types of cancer, and the molecular mechanisms implicated in aging, progeria syndromes, and cancer pathogenesis display considerable similarities. Maintaining redox homeostasis, efficient signal transduction, and mitochondrial metabolism is essential for genome integrity and for preventing progression to cellular senescence or tumorigenesis. NAD+ is a central signaling molecule involved in these and other cellular processes implicated in age-related diseases and cancer. Growing evidence implicates NAD+ decline as a major feature of accelerated aging progeria syndromes and normal aging. Administration of NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) offer promising therapeutic strategies to improve health, progeria comorbidities, and cancer therapies. This review summarizes insights from the study of aging and progeria syndromes and discusses the implications and therapeutic potential of the underlying molecular mechanisms involved in aging and how they may contribute to tumorigenesis.","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2019-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1146/ANNUREV-CANCERBIO-030518-055905","citationCount":"41","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual Review of Cancer Biology-Series","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/ANNUREV-CANCERBIO-030518-055905","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 41

Abstract

Aging is a major risk factor for many types of cancer, and the molecular mechanisms implicated in aging, progeria syndromes, and cancer pathogenesis display considerable similarities. Maintaining redox homeostasis, efficient signal transduction, and mitochondrial metabolism is essential for genome integrity and for preventing progression to cellular senescence or tumorigenesis. NAD+ is a central signaling molecule involved in these and other cellular processes implicated in age-related diseases and cancer. Growing evidence implicates NAD+ decline as a major feature of accelerated aging progeria syndromes and normal aging. Administration of NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) offer promising therapeutic strategies to improve health, progeria comorbidities, and cancer therapies. This review summarizes insights from the study of aging and progeria syndromes and discusses the implications and therapeutic potential of the underlying molecular mechanisms involved in aging and how they may contribute to tumorigenesis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
衰老与癌症中的NAD+代谢
衰老是许多类型癌症的主要危险因素,与衰老、早衰综合征和癌症发病机制相关的分子机制显示出相当大的相似性。维持氧化还原稳态、有效的信号转导和线粒体代谢对于基因组完整性和防止细胞衰老或肿瘤发生至关重要。NAD+是一种中枢信号分子,参与与年龄相关疾病和癌症相关的这些和其他细胞过程。越来越多的证据表明NAD+下降是加速衰老早衰综合征和正常衰老的主要特征。NAD+前体如烟酰胺核苷(NR)和烟酰胺单核苷酸(NMN)的管理为改善健康、早衰合并症和癌症治疗提供了有希望的治疗策略。本文综述了衰老和早衰综合征的研究成果,并讨论了衰老的潜在分子机制及其对肿瘤发生的影响和治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
14.50
自引率
1.30%
发文量
13
期刊介绍: The Annual Review of Cancer Biology offers comprehensive reviews on various topics within cancer research, covering pivotal and emerging areas in the field. As our understanding of cancer's fundamental mechanisms deepens and more findings transition into targeted clinical treatments, the journal is structured around three main themes: Cancer Cell Biology, Tumorigenesis and Cancer Progression, and Translational Cancer Science. The current volume of this journal has transitioned from gated to open access through Annual Reviews' Subscribe to Open program, ensuring all articles are published under a CC BY license.
期刊最新文献
Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer Next-Generation Estrogen Receptor–Targeted Therapeutics Engineering the Immune Microenvironment into Organoid Models The Effects of Clonal Heterogeneity on Cancer Immunosurveillance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1